A Phase 4 interventional study of dexamethasone intravitreal implant and ranibizumab in Retinal Vein Occlusion and Macular Edema, sponsored by Allergan. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 6th largest by enrollment, is one of 5 that started in 2011, is one of 13 in phase 4, and was the 20th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 14 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 47 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
17 studies in Retinal Vein Occlusion by AbbVie: none open now, none under way, none of them phase 3. Of 17 finished, 14 (82%) have results posted.
Among the 17 studies in Retinal Vein Occlusion by AbbVie, this one is one of 5 that started in 2011, is one of 3 in phase 4, and was the 6th registered.
AbbVie’s Retinal Vein Occlusion studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 17 in Retinal Vein Occlusion:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
Drug: dexamethasone intravitreal implant
Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
Biological: ranibizumab
Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
Also known as: Ozurdex®
Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
Also known as: Lucentis®
Change From Baseline in Best Corrected Visual Acuity (BCVA)
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity) A positive change from Baseline (more letters read correctly) indicates improvement.
Time frame: Baseline, Month 12
Change From Baseline in Central Retinal Subfield Thickness Using Optical Coherence Tomography (OCT)
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Month 12. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 12
Percentage of Patients With 15-or-More Letter Improvement in BCVA
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved.
Time frame: Baseline, Month 12
Percentage of Patients With a 15-or-More Letter Decrease in BCVA
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
Time frame: Baseline, Month 12
Time to BCVA Improvement of 15-or-More Letters
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The time in days to BCVA improvement of 15-or-More letters.
Time frame: 12 Months
Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)
The VFQ-25 includes 25 vision-targeted questions plus one general health question which assess visual impairment on functioning and specific aspects of health-related quality of life for a total possible composite score of 0 (worst) to 100 (best functionality). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 12
Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure
Treatment failure was defined as withdrawal of the participant from treatment or from the study by the investigator before the final visit because of a lack of efficacy.
Time frame: 12 Months
| Milestone | Ozurdex® | Lucentis® |
|---|---|---|
| Started | 154 | 153 |
| Completed | 112 | 139 |
| Not completed | 42 | 14 |
| Withdrew: Adverse event | 18 | 2 |
| Withdrew: No further treatment benefit expected | 5 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Withdrawal of consent | 2 | 2 |
| Withdrew: Protocol violation | 6 | 4 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Other miscellaneous reasons | 6 | 4 |
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity) A positive change from Baseline (more letters read correctly) indicates improvement.
| letters | Ozurdex® | Lucentis® |
|---|---|---|
| Baseline (n=153,153) | 56.6 ± 10.89 | 59.2 ± 10.92 |
| Change from Baseline at Month 12 (n=153,151) | 7.9 ± 14.42 | 16.9 ± 12.08 |
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Month 12. A negative change from Baseline indicates improvement.
| microns | Ozurdex® | Lucentis® |
|---|---|---|
| Baseline (n=149, 149) | 553.2 ± 170.15 | 561.0 ± 188.93 |
| Change from Baseline at Month 12 (n=140,144) | -219.2 ± 180.51 | -253.5 ± 197.08 |
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved.
| percentage of participants | Ozurdex® | Lucentis® |
|---|---|---|
| Percentage of Patients With 15-or-More Letter Improvement in BCVA | 33.8 | 59.5 |
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
| percentage of participants | Ozurdex® | Lucentis® |
|---|---|---|
| Percentage of Patients With a 15-or-More Letter Decrease in BCVA | 9.1 | 0.7 |
BCVA was measured in the study eye using an eye chart and was recorded as the number of letters read correctly for a total possible score of 0 to 100. The time in days to BCVA improvement of 15-or-More letters.
| days | Ozurdex® | Lucentis® |
|---|---|---|
| Time to BCVA Improvement of 15-or-More Letters | 73.7 ± 79.68 | 82.0 ± 93.78 |
The VFQ-25 includes 25 vision-targeted questions plus one general health question which assess visual impairment on functioning and specific aspects of health-related quality of life for a total possible composite score of 0 (worst) to 100 (best functionality). A positive change from Baseline indicates improvement.
| score on a scale | Ozurdex® | Lucentis® |
|---|---|---|
| Baseline (n=143,139) | 78.1 ± 16.58 | 80.7 ± 14.34 |
| Change from Baseline at Month 12 (n=143, 139) | 3.5 ± 12.21 | 6.6 ± 13.45 |
Treatment failure was defined as withdrawal of the participant from treatment or from the study by the investigator before the final visit because of a lack of efficacy.
| percentage of participants | Ozurdex® | Lucentis® |
|---|---|---|
| Percentage of Participants Not Completing the Month 12 Visit Due to Treatment Failure | 4.5 | 0.7 |
Collected over Up to 60 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ozurdex® | — | 12/153 (7.8%) | 127/153 (83%) |
| Lucentis® | — | 16/150 (10.7%) | 104/150 (69.3%) |
| Event | Ozurdex® | Lucentis® |
|---|---|---|
| Angina pectorisCardiac disorders | 0/153 | 1/150 |
| Myocardial infarctionCardiac disorders | 0/153 | 1/150 |
| Myocardial ischaemiaCardiac disorders | 0/153 | 1/150 |
| PalpitationsCardiac disorders | 0/153 | 1/150 |
| Subarachnoid haemorrhageNervous system disorders | 0/153 | 1/150 |
| AnxietyPsychiatric disorders | 0/153 | 1/150 |
| Catheter site related reactionGeneral disorders | 0/153 | 1/150 |
| Diverticulum intestinalGastrointestinal disorders | 0/153 | 1/150 |
| Gastric ulcerGastrointestinal disorders | 0/153 | 1/150 |
| HaematemesisGastrointestinal disorders | 0/153 | 1/150 |
| Event | Ozurdex® | Lucentis® |
|---|---|---|
| Intraocular pressure increasedInvestigations | 50/153 | 16/150 |
| Conjunctival haemorrhageEye disorders | 28/153 | 17/150 |
| Macular oedemaEye disorders | 20/153 | 4/150 |
| Visual acuity reducedEye disorders | 18/153 | 3/150 |
| CataractEye disorders | 13/153 | 2/150 |
| HypertensionVascular disorders | 5/153 | 10/150 |
| Lenticular opacitiesEye disorders | 10/153 | 0/150 |
| Vitreous floatersEye disorders | 9/153 | 9/150 |
| Eye painEye disorders | 6/153 | 9/150 |
| ConjunctivitisEye disorders | 6/153 | 9/150 |
| Age, Continuous(years) | Ozurdex® | Lucentis® | Total |
|---|---|---|---|
| Mean | 68.4 ± 10.58 | 65.5 ± 12.04 | 67.0 ± 11.41 |
| Sex: Female, Male(Participants) | Ozurdex® | Lucentis® | Total |
|---|---|---|---|
| Female | 62 | 66 | 128 |
| Male | 92 | 87 | 179 |
Ran from Oct 2011 to primary completion in Nov 2014, 36 months.
Results were first posted in Feb 2016, 1 year 3 months after primary completion.
Of 19 phase 4 interventional studies under Retinal Vein Occlusion, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone Intravitreal Implant · Ranibizumab